On October 12, 2026, Nasdaq notified Lucid Diagnostics that its common stock closed below $1.00 for 30 consecutive business days, violating Listing Rule 5550(a)(2). The company has until April 12, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive trading days. Failure to meet this requirement may result in delisting proceedings. Lucid Diagnostics operates in the diagnostics industry.
